secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2024-01-11T23:59:59+00:00
Accession:  0001628280-24-001163
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion provides FY2024 operating expense guidance of $225M-$245M
------------------------------------------------------------------

- R&D expenses expected $45M-$55M for FY2024.
- SG&A expenses expected $180M-$190M for FY2024.
- Total operating expenses guided at $225M-$245M.
- Guidance announced at 42nd Annual J.P. Morgan Healthcare Conference on Jan 10, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828024001163/0001628280-24-001163-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828024001163/espr-20240110.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-001163

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer